Because the ubiquitin proteasome system is essential for normal cellular function, safety considerations are central to proteasome-targeting therapy. Controlled inhibition is critical to avoid excessive disruption of healthy tissues.

Side effects generally arise from temporary interference with protein turnover in rapidly dividing or metabolically active cells. These effects are typically manageable with appropriate dosing schedules and monitoring.

Importantly, healthy cells often recover more effectively than diseased cells once treatment pauses, due to lower baseline protein stress. This differential recovery underpins the therapeutic window of proteasome drugs.

Ongoing refinement of dosing strategies aims to maximize therapeutic benefit while maintaining patient comfort and safety. Continuous evaluation of tolerability supports individualized treatment decisions.